Molecular imaging of diabetic pancreas

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 216-223

  Kavishwar, Amol ^a   Moore, Anna ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antibody; Beta cells; Chromatography; Diabetes; IC2 MRI; Imaging; Proteomics; Targetsphingomyelin

Indexed keywords

CHLORPROPAMIDE; ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; EXENDIN 4; FC RECEPTOR; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; METABOTROPIC RECEPTOR 5; REPAGLINIDE; SPHINGOMYELIN; SULFONYLUREA RECEPTOR 1; SYNEXIN; TOLBUTAMIDE; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; CELL LOSS; CELL SURFACE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIABETES MELLITUS; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; IMMUNOCHEMISTRY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MOLECULAR IMAGING; MOLECULAR WEIGHT; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS BLOOD FLOW; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; PROTEOMICS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84866349590     PISSN: 18715222     EISSN: 18756115     Source Type: Journal    
DOI: 10.2174/187152212802001884     Document Type: Article

References (66)

1. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27(5), 1047-1053.
2. Knowler, W.C.; Barrett-Connor, E.; Fowler, S.E.; Hamman, R.F.; Lachin, J.M.; Walker, E.A.; Nathan, D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med., 2002, 346(6), 393-403.
3. Herold, K.C.; Gitelman, S.; Greenbaum, C.; Puck, J.; Hagopian, W.; Gottlieb, P.; Sayre, P.; Bianchine, P.; Wong, E.; Seyfert-Margolis, V.; Bourcier, K.; Bluestone, J.A. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin. Immunol., 2009, 132(2), 166-173.
4. Robertson, R.P. Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient? Diabetes, 2007, 56(10), 2420-2424.
5. Halban, P.A. Cellular sources of new pancreatic beta cells and therapeutic implications for regenerative medicine. Nat. Cell Biol., 2004, 6(11), 1021-1025.
6. Sweet, I.R.; Cook, D.L.; Lernmark, A.; Greenbaum, C.J.; Krohn, K.A. Non-invasive imaging of beta cell mass: a quantitative analysis. Diabetes Technol. Ther., 2004, 6(5), 652-659.
7. Sweet, I.R.; Cook, D.L.; Lernmark, A.; Greenbaum, C.J.; Wallen, A.R.; Marcum, E.S.; Stekhova, S.A.; Krohn, K.A. Systematic screening of potential beta-cell imaging agents. Biochem. Biophys. Res. Commun., 2004, 314(4), 976-983.
8. Moore, A.; Medarova, Z. Approaches for imaging the diabetic pancreas: First results. Immunol., Endoc. Metab. Agents Med. Chem., 2004, 4(2), 1-17.
9. Ahmed, M.; Forsberg, J.; Bergsten, P. Protein profiling of human pancreatic islets by two-dimensional gel electrophoresis and mass spectrometry. J. Proteome Res., 2005, 4(3), 931-940.
10. Han, D.; Moon, S.; Kim, H.; Choi, S.E.; Lee, S.J.; Park, K.S.; Jun, H.; Kang, Y.; Kim, Y. Detection of differential proteomes associated with the development of type 2 diabetes in the Zucker rat model using the iTRAQ technique. J. Proteome Res., 2011, 10(2), 564-577.
11. Lindskog, C.; Asplund, A.; Engkvist, M.; Uhlen, M.; Korsgren, O.; Ponten, F. Antibody-based proteomics for discovery and exploration of proteins expressed in pancreatic islets. Discov. Med., 2010, 9(49), 565-578.
12. Bouckenooghe, T.; Flamez, D.; Ortis, F.; Goldman, S.; Eizirik, D.L. Identification of new pancreatic beta cell targets for in vivo imaging by a systems biology approach. Curr. Pharm. Des., 2010, 16(14), 1609-1618.
13. Flamez, D.; Roland, I.; Berton, A.; Kutlu, B.; Dufrane, D.; Beckers, M.C.; De Waele, E.; Rooman, I.; Bouwens, L.; Clark, A.; Lonneux, M.; Jamar, J.F.; Goldman, S.; Marechal, D.; Goodman, N.; Gianello, P.; Van Huffel, C.; Salmon, I.; Eizirik, D.L. A genomic-based approach identifies FXYD domain containing ion transport regulator 2 (FXYD2)gammaa as a pancreatic beta cell-specific biomarker. Diabetologia, 2010, 53(7), 1372-1383.
14. Cline, G.W.; Zhao, X.; Jakowski, A.B.; Soeller, W.C.; Treadway, J.L. Islet-selectivity of G-protein coupled receptor ligands evaluated for PET imaging of pancreatic beta-cell mass. Biochem. Biophys. Res. Commun., 2011, 412(3), 413-418.
15. Hald, J.; Galbo, T.; Rescan, C.; Radzikowski, L.; Sprinkel, A.E.; Heimberg, H.; Ahnfelt-Ronne, J.; Jensen, J.; Scharfmann, R.; Gradwohl, G.; Kaestner, K.H.; Stoeckert, C., Jr.; Jensen, J.N.; Madsen, O.D. Pancreatic islet and progenitor cell surface markers with cell sorting potential. Diabetologia, 2012, 55(1), 154-165.
16. Dorrell, C.; Abraham, S.L.; Lanxon-Cookson, K.M.; Canaday, P.S.; Streeter, P.R.; Grompe, M. Isolation of major pancreatic cell types and long-term culture-initiating cells using novel human surface markers. Stem Cell Res., 2008, 1(3), 183-194.
17. Dorrell, C.; Grompe, M.T.; Pan, F.C.; Zhong, Y.; Canaday, P.S.; Shultz, L.D.; Greiner, D.L.; Wright, C.V.; Streeter, P.R.; Grompe, M. Isolation of mouse pancreatic alpha, beta, duct and acinar populations with cell surface markers. Mol. Cell Endocrinol., 2011, 339(1-2), 144-150.
18. Liu, G.; Dou, S.; Cheng, D.; Leif, J.; Rusckowski, M.; Streeter, P.R.; Shultz, L.D.; Hnatowich, D.J.; Greiner, D.L. Human islet cell MORF/cMORF pretargeting in a xenogeneic murine transplant model. Mol. Pharm., 2011, 8(3), 767-773.
19. Liu, G.; Dou, S.; Akalin, A.; Rusckowski, M.; Streeter, P.R.; Shultz, L.D.; Greiner, D.L. Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody. Nucl. Med. Biol., 2012. [Epub ahead of print]
20. Brogren, C.H.; Hirsch, F.; Wood, P.; Druet, P.; Poussier, P. Production and characterization of a monoclonal islet cell surface autoantibody from the BB rat. Diabetologia, 1986, 29(5), 330-333.
21. Moore, A.; Bonner-Weir, S.; Weissleder, R. Noninvasive in vivo measurement of beta-cell mass in mouse model of diabetes. Diabetes, 2001, 50(10), 2231-2236.
22. Kavishwar, A.; Medarova, Z.; Moore, A. Unique sphingomyelin patches are targets of a beta-cell-specific antibody. J. Lipid Res., 2011, 52(9), 1660-1671.
23. Ueberberg, S.; Meier, J.J.; Waengler, C.; Schechinger, W.; Dietrich, J.W.; Tannapfel, A.; Schmitz, I.; Schirrmacher, R.; Koller, M.; Klein, H.H.; Schneider, S. Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic beta- or alpha-cells in vivo. Diabetes, 2009, 58(10), 2324-2334.
24. Samli, K.N.; McGuire, M.J.; Newgard, C.B.; Johnston, S.A.; Brown, K.C. Peptide-mediated targeting of the islets of Langerhans. Diabetes, 2005, 54(7), 2103-2108.
25. Schneider, S.; Feilen, P.J.; Schreckenberger, M.; Schwanstecher, M.; Schwanstecher, C.; Buchholz, H.G.; Thews, O.; Oberholzer, K.; Korobeynikov, A.; Bauman, A.; Comagic, S.; Piel, M.; Schirrmacher, E.; Shiue, C.Y.; Alavi, A.A.; Bartenstein, P.; Rosch, F.; Weber, M.M.; Klein, H.H.; Schirrmacher, R. In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans. Exp. Clin. Endocrinol. Diabetes, 2005, 113(7), 388-395.
26. Oh, C.S.; Kohanim, S.; Kong, F.L.; Song, H.C.; Huynh, N.; Mendez, R.; Chanda, M.; Edmund Kim, E.; Yang, D.J. Sulfonylurea receptor as a target for molecular imaging of pancreas beta cells with (99m)Tc-DTPA-glipizide. Ann. Nucl. Med., 2012, 26(3), 253-261.
27. Maffei, A.; Liu, Z.; Witkowski, P.; Moschella, F.; Del Pozzo, G.; Liu, E.; Herold, K.; Winchester, R.J.; Hardy, M.A.; Harris, P.E. Identification of tissue-restricted transcripts in human islets. Endocrinology, 2004, 145(10), 4513-4521.
28. Pettibone, D.J.; Totaro, J.A.; Pflueger, A.B. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur. J. Pharmacol., 1984, 102(3-4), 425-430.
29. Simpson, N.R.; Souza, F.; Witkowski, P.; Maffei, A.; Raffo, A.; Herron, A.; Kilbourn, M.; Jurewicz, A.; Herold, K.; Liu, E.; Hardy, M.A.; Van Heertum, R.; Harris, P.E. Visualizing pancreatic beta-cell mass with [11C]DTBZ. Nucl. Med. Biol., 2006, 33(7), 855-864.
30. Souza, F.; Freeby, M.; Hultman, K.; Simpson, N.; Herron, A.; Witkowsky, P.; Liu, E.; Maffei, A.; Harris, P.E. Current progress in non-invasive imaging of beta cell mass of the endocrine pancreas. Curr. Med. Chem., 2006, 13(23), 2761-2773.
31. Souza, F.; Simpson, N.; Raffo, A.; Saxena, C.; Maffei, A.; Hardy, M.; Kilbourn, M.; Goland, R.; Leibel, R.; Mann, J.J.; Van Heertum, R.; Harris, P.E. Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model. J. Clin. Invest., 2006, 116(6), 1506-1513.
32. Bohnen, N.I.; Albin, R.L.; Koeppe, R.A.; Wernette, K.A.; Kilbourn, M.R.; Minoshima, S.; Frey, K.A. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J. Cereb. Blood Flow Metab., 2006, 26(9), 1198-1212.
33. Goland, R.; Freeby, M.; Parsey, R.; Saisho, Y.; Kumar, D.; Simpson, N.; Hirsch, J.; Prince, M.; Maffei, A.; Mann, J.J.; Butler, P.C.; Van Heertum, R.; Leibel, R.L.; Ichise, M.; Harris, P.E. 11Cdihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J. Nucl. Med., 2009, 50(3), 382-389.
34. Kung, M.P.; Hou, C.; Lieberman, B.P.; Oya, S.; Ponde, D.E.; Blankemeyer, E.; Skovronsky, D.; Kilbourn, M.R.; Kung, H.F. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J. Nucl. Med., 2008, 49(7), 1171-1176.
35. Singhal, T.; Ding, Y.S.; Weinzimmer, D.; Normandin, M.D.; Labaree, D.; Ropchan, J.; Nabulsi, N.; Lin, S.F.; Skaddan, M.B.; Soeller, W.C.; Huang, Y.; Carson, R.E.; Treadway, J.L.; Cline, G.W. Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes. Mol. Imaging Biol., 2011, 13(5), 973-984.
36. Eng, J.; Andrews, P.C.; Kleinman, W.A.; Singh, L.; Raufman, J.P. Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J. Biol. Chem., 1990, 265(33), 20259-20262.
37. Eng, J.; Kleinman, W.A.; Singh, L.; Singh, G.; Raufman, J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem., 1992, 267(11), 7402-7405.
38. Goke, R.; Fehmann, H.C.; Linn, T.; Schmidt, H.; Krause, M.; Eng, J.; Goke, B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1(7-36)-amide receptor of insulin-secreting beta-cells. J. Biol. Chem., 1993, 268(26), 19650-19655.
39. Wicki, A.; Wild, D.; Storch, D.; Seemayer, C.; Gotthardt, M.; Behe, M.; Kneifel, S.; Mihatsch, M.J.; Reubi, J.C.; Macke, H.R.; Christofori, G. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin. Cancer Res., 2007, 13(12), 3696-3705.
40. Wild, D.; Behe, M.; Wicki, A.; Storch, D.; Waser, B.; Gotthardt, M.; Keil, B.; Christofori, G.; Reubi, J.C.; Macke, H.R. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J. Nucl. Med., 2006, 47(12), 2025-2033.
41. Mukai, E.; Toyoda, K.; Kimura, H.; Kawashima, H.; Fujimoto, H.; Ueda, M.; Temma, T.; Hirao, K.; Nagakawa, K.; Saji, H.; Inagaki, N. GLP-1 receptor antagonist as a potential probe for pancreatic beta-cell imaging. Biochem. Biophys. Res. Commun., 2009, 389(3), 523-526.
42. Wang, Y.; Lim, K.; Normandin, M.; Zhao, X.; Cline, G.W.; Ding, Y.S. Synthesis and evaluation of [(18)F]exendin (9-39) as a potential biomarker to measure pancreatic beta-cell mass. Nucl. Med. Biol., 2012, 39(2), 167-176.
43. Reiner, T.; Kohler, R.H.; Liew, C.W.; Hill, J.A.; Gaglia, J.; Kulkarni, R.N.; Weissleder, R. Near-infrared fluorescent probe for imaging of pancreatic beta cells. Bioconjug. Chem., 2010, 21(7), 1362-1368.
44. Reiner, T.; Thurber, G.; Gaglia, J.; Vinegoni, C.; Liew, C.W.; Upadhyay, R.; Kohler, R.H.; Li, L.; Kulkarni, R.N.; Benoist, C.; Mathis, D.; Weissleder, R. Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin4 analog. Proc. Natl. Acad. Sci. USA, 2011, 108(31), 12815-12820.
45. De Paepe, M.E.; Corriveau, M.; Tannous, W.N.; Seemayer, T.A.; Colle, E. Increased vascular permeability in pancreas of diabetic rats: detection with high resolution protein A-gold cytochemistry. Diabetologia, 1992, 35(12), 1118-1124.
46. Majno, G.; Joris, I.; Handler, E.S.; Desemone, J.; Mordes, J.P.; Rossini, A.A. A pancreatic venular defect in the BB/Wor rat. Am. J. Pathol., 1987, 128(2), 210-215.
47. Sandler, S.; Jansson, L. Vascular permeability of pancreatic islets after administration of streptozotocin. Virchows Arch. A. Pathol. Anat. Histopathol., 1985, 407(4), 359-367.
48. Denis, M.C.; Mahmood, U.; Benoist, C.; Mathis, D.; Weissleder, R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc. Natl. Acad. Sci. USA, 2004, 101(34), 12634-12639.
49. Turvey, S.E.; Swart, E.; Denis, M.C.; Mahmood, U.; Benoist, C.; Weissleder, R.; Mathis, D. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J. Clin. Invest, 2005, 115(9), 2454-2461.
50. Medarova, Z.; Castillo, G.; Dai, G.; Bolotin, E.; Bogdanov, A.; Moore, A. Noninvasive magnetic resonance imaging of microvascular changes in type 1 diabetes. Diabetes, 2007, 56(11), 2677-2682.
51. Bottazzo, G.F.; Dean, B.M.; McNally, J.M.; MacKay, E.H.; Swift, P.G.; Gamble, D.R. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med., 1985, 313(6), 353-360.
52. Gepts, W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes, 1965, 14(10), 619-633.
53. Imagawa, A.; Hanafusa, T.; Tamura, S.; Moriwaki, M.; Itoh, N.; Yamamoto, K.; Iwahashi, H.; Yamagata, K.; Waguri, M.; Nanmo, T.; Uno, S.; Nakajima, H.; Namba, M.; Kawata, S.; Miyagawa, J.I.; Matsuzawa, Y. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes, 2001, 50(6), 1269-1273.
54. Shapiro, E.M.; Sharer, K.; Skrtic, S.; Koretsky, A.P. In vivo detection of single cells by MRI. Magn. Reson. Med., 2006, 55(2), 242-249.
55. Kavishwar, A.; Medarova, Z.; Moore, A. In: Nanotechnology and Nanomedicine in Diabetes. Le, L.-A.; Hunter, R.J.; Preedy, V.R., Eds.; CRC Press: London, 2012; pp. 287-303.
56. Bulte, J.W.; Kraitchman, D.L. Monitoring cell therapy using iron oxide MR contrast agents. Curr. Pharm. Biotechnol., 2004, 5(6), 567-584.
57. Schulze, E.; Ferrucci, J.T., Jr.; Poss, K.; Lapointe, L.; Bogdanova, A.; Weissleder, R. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest. Radiol., 1995, 30(10), 604-610.
58. Moore, A.; Weissleder, R.; Bogdanov, A., Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J. Magn. Reson. Imaging, 1997, 7(6), 1140-1145.
59. Schoepf, U.; Marecos, E.M.; Melder, R.J.; Jain, R.K.; Weissleder, R. Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies. Biotechniques, 1998, 24(4), 642-646, 648-651.
60. Shen, T.T.; Bogdanov, A., Jr.; Bogdanova, A.; Poss, K.; Brady, T.J.; Weissleder, R. Magnetically labeled secretin retains receptor affinity to pancreas acinar cells. Bioconjug. Chem., 1996, 7(3), 311-316.
61. Moore, A.; Basilion, J.P.; Chiocca, E.A.; Weissleder, R. Measuring transferrin receptor gene expression by NMR imaging. Biochim. Biophys. Acta, 1998, 1402(3), 239-249.
62. Medarova, Z.; Tsai, S.; Evgenov, N.; Santamaria, P.; Moore, A. In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression. Magn. Reson. Med., 2008, 59(4), 712-720.
63. Moore, A.; Sun, P.Z.; Cory, D.; Hogemann, D.; Weissleder, R.; Lipes, M.A. MRI of insulitis in autoimmune diabetes. Magn. Reson. Med., 2002, 47(4), 751-758.
64. Moore, A.; Medarova, Z.; Potthast, A.; Dai, G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res., 2004, 64(5), 1821-1827.
65. Billotey, C.; Aspord, C.; Beuf, O.; Piaggio, E.; Gazeau, F.; Janier, M.F.; Thivolet, C. T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging. Radiology, 2005, 236(2), 579-587.
66. Tsai, S.; Shameli, A.; Santamaria, P. CD8+ T cells in type 1 diabetes. Adv. Immunol., 2008, 100, 79-124.